scienceOct 27, 202423:46pending

Ep. 119: Phase 2 HOPE clinical trial results

About this episode

Moderator: Theodoros M. Mavridis (Dublin, Ireland) Guest: Messoud Ashina (Glostrup, Denmark) In this episode Theodoros M. Mavridis and Messoud Ashina delve into the findings of the Phase 2 HOPE clinical trial, which assesses the efficacy and safety of Lu AG09222, a monoclonal antibody that targets the PACAP pathway. They explore the potential of this innovative treatment for migraine prevention while highlighting the critical role of the PACAP pathway in migraine pathophysiology.

Get every episode summarized

Each time eanCast: Weekly Neurology publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.

Email me new episodes

Free for 3 shows. No card needed.

Hosts & guests

eean.orgHost

No transcript yet

This episode has not been transcribed. Request it and it moves to the front of the queue.

More episodes

Ep. 119: Phase 2 HOPE clinical trial results

About this episode

Get every episode summarized

Hosts & guests

More from eanCast: Weekly Neurology

Ep. 193: Understanding GBS and other inflammatory neuropathies across ages

Ep. 192: Movement disorders in children and adults: different or the same?

Ep. 191: FND in children and adults: different or the same?

Ep. 190: Parkinson’s disease – more than a movement disorder